Context Therapeutics Inc. (CNTX), a biopharmaceutical company, Monday announced, that it has appointed Andy Pasternak as Chairman of its Board of Directors. Pasternak succeeds Richard Berman, who stepped down from the Board on January 12.
Pasternak has most recently served as Executive Vice President and Chief Strategy Officer at Horizon Therapeutics, a biotechnology company specializing in therapies for serious and rare autoimmune diseases.
CNTX is currently trading at $1.05, down 2.78 percent or $0.03 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.